74 results about "Infarct size" patented technology

A method and apparatus for prevention and reduction of myocardial infarct size and / or expansion and heart remodeling by partial, controllable and reversible obstruction of the venous blood flow to the heart. As a result, the ventricular wall stress and dilation are reduced. Blood flow is maintained at a safe level for the duration of treatment. The apparatus consists of a catheter with an occlusion balloon and a control and monitoring system.

A cardiac rhythm management (CRM) system provides for post-myocardial infarction (MI) therapy with closed-loop control using one or more ultrasound transducers sensing one or more ultrasound signals indicative of cardiac dimensions. Cardiac size parameters are produced using the one or more ultrasound signals to represent, for example, cardiac chamber diameter, cardiac chamber volume, cardiac wall thickness, infarct size, and degree of change in any of these parameters over time or between measurements. In various embodiments, such cardiac size parameters provide for titration, safety check, and acute optimization of the post-MI therapy.

A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second value. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.

We describe a particle secreted by a mesenchymal stem cell and comprising at least one biological property of a mesenchymal stem cell. The biological property may comprise a biological activity of a mesenchymal stem cell conditioned medium (MSC- CM) such as cardioprotection or reduction of infarct size. The particle may comprise a vesicle or an exosome.

The described invention provides pharmaceutical compositions for treating an infarct area injury and methods of treating or repairing the infarct area injury in a revascularized subject in the aftermath of an acute myocardial infarction resulting from a natural disease process by administering to the subject parenterally through a catheter a sterile pharmaceutical composition containing a therapeutically effective amount of a nonexpanded sterile isolated chemotactic hematopoietic stem cell product as a first therapeutic agent and optionally a therapeutically effective amount of at least one compatible second therapeutic agent. The infarct area-improving amount of the sterile isolated chemotactic hematopoietic stem cell product comprises an enriched population of isolated autologous CD34+ cells containing a subpopulation of potent cells expressing CXCR-4 and having CXCR-4-mediated chemotactic activity such that the enriched population of isolated autologous CD34+ hematopoietic stem cells provides at least 0.5×106 potent CD34+ cells expressing CXCR-4 and having CXCR-4 mediated chemotactic activity.

A system and method in accordance with the present invention provides a infusion catheter that is flexible, has such a smooth traction and a low profile to minimize break up of the obstruction when crossing it, can access distal vasculature quickly, is easy to use and readily to be implemented in the conventional PCI. Another object is to provide a method that can be performed within a short period of time and employs the catheter described herein to infuse a therapeutic agent distally to the obstruction before it is removed as a means of reducing reperfusion injury, protecting distal vasculature and microcirculation, preserving myocytes, reducing infarct size and ischemic damages in the heart, brain, lung, liver, kidney and limb. Another object is to provide complementary feature options to the infusion catheter and the aspiration catheter to improve the speed and quality of the vessel clearance.

The present invention relates to a new means for the treatment of focal ischemic cerebral infarction (ischemic stroke). It has been found that reduction of α2-antiplasmin leads to a significantly smaller focal cerebral infarct size. The invention therefore provides the use of compounds that reduce α2-antiplasmin concentration or activity in vivo, for the preparation of a therapeutical composition for the treatment of focal cerebral ischemic infarction (ischemic stroke).

A method for improving clinical outcome in focal ischemic stroke in a mammal by increasing cerebral blood flow and / or reducing infarct size is described which involves administering an effective amount of an ant-CD18 antibody to the mammal, in the absence of removal of the arterial obstruction.

A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second dvalue. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.

The invention relates to a drug compound used to treat ischemia cerebrovascular disease, which is formed by panaxoside and bilobalide, wherein, the invention can significantly reduce the infarct size of brain to treat the ischemia condition, cerebral thrombus or the like.

An orally taken Chinese medicine for treating cardiovascular and cerebrovascular diseases (coronary heart disease and apoplexy for example) is prepared from red sage root and safflower through extracting their active components and dispensing the medicine.

This invention relates to a pharmaceutical composition for preventing and curing myocardium ischemia and reducing area of myocardial infarction, its pharmaceutical preparation and applications. The composition includes (a) levocarnitine or its derivatives, and (b) trimetazidine or its medicative salts. The quantity of levocarnitine or its derivatives, and trimetazidine or its medicative salts in the composition is effective amount for treating myocardial ischemia and reducing the area of myocardial infarction.

The present invention relates to compositions and methods for prophylactic and / or therapeutic treatment of conditions related to mitochondrial function. In various aspects, the present invention comprises administering one or more compounds selected from the group consisting of epicatechin, an epicatechin derivative, catechin, a catechin derivative, nicorandil, and a nicorandil derivative in an amount effective to stimulate mitochondrial function in cells. The methods and compositions described herein provide for reducing infarct size in the heart following permanent ischemia or ischemia / reperfusion (IR) event or method for delaying, attenuating or preventing adverse cardiac remodeling, and can assist in prevention of impaired mitochondria biogenesis and thus prevention of the consequences of impaired mitochondrial biogenesis in various diseases and conditions, as well as provide for the active therapy of mitochondrial depletion that may have already occurred.

The present invention provides compositions and methods for the following: preventing and treating heart failure; preventing heart failure in a patient with a pre-heart failure condition; treating and preventing heart failure with ischemic and non-ischemic causes; treating and preventing heart failure in a subject status post myocardial infarction; reversing damage to the heart following myocardial infarction; by administering to a subject an effective amount of an adrenergic beta-agonist either alone or in combination with an effective amount of an adrenergic beta-1 antagonist. FIG. 1 is a bar graph representing relative infarct sizes, as expressed as a percentage of left ventricular circumference.

The present invention is related to benzothiophen-2-carbonylguanidine derivatives, a preparation method thereof, and pharmaceutical compositions containing the same. The derivatives have potent inhibitory effect on the sodium / hydrogen exchanger NHE-I, improve the functional recovery of ischemia / reperfusion-induced heart injury in isolated ischemic heart models, and significantly reduce the myocardiac infarct size in in vivo ischemic animal models, thereby showing excellent cardioprotective effects. Also, the derivatives are protective of both neuronal cells and the brain as proven by their protective effects on neuronal cells from necrosis and apoptosis and by their ability to significantly reduce cerebral infarct sizes in in vivo ischemic brain models. The derivatives can be effectively used for the prevention and treatment of ischemic heart diseases such as myocardiac infarction, arrhythmia, angina pectoris and the like, and cerebrovascular diseases such as cerebral stroke and be used as cardioprotective agents to the patients undergoing reperfusion therapy including chemicals such as thrombolytic agents, or surgery such as coronary artery bypass and percutaneous transluminal coronary angioplasty.

The invention relates to a health soup for curing myocardial infarction, which consists of the main components of 10-15 grams of dried raw ginseng, 2 grams of radix scutellariae, 15 grams of raw radix astragali, 15 grams of radix salviae miltiorrhizae, 10 grams of radix angelicae sinensis, 10 grams of corydalis tuber, 5 grams of radix sophorae falvescentis, 10 grams of hemlock parsley vines, 5 grams of climbing nightshade, 12 grams of patchouli, 10 grams of Eupatorium fortunei Turcz., 10 grams of dried orange peel, 10 grams of tuber pinellia, 6-10 grams of rhubarb and other Chinese traditional medicines. A preparation method comprises the following steps: putting the herbal medicines into a pottery jar, adding water for soaking for 20 minutes, decocting for 15 minutes with mild fires, and taking 250 grams of liquid medicine for administration twice per day; the dosages in the prescription are all natural Chinese herbal medicines, the medicinal properties of the Chinese herbal medicines are reserved, and the health soup has the functions of improving the vitality of myocardial cells, improving the microcirculation of cardiac muscles, restoring the damaged cardiac muscles, and reducing infarct sizes.

The present invention is one kind of red peony injection prepared with red peony root as material and through alcohol extraction, n-butanol extraction or macroporous resin purification, and adding proper amount of medicinal supplementary material and injection water. It is stable and may be used in intramuscular injection, intravenous injection and intravenous instillation. Pharmacodynamic experiment shows that the medicine of the present invention can improve the behavior disorder of rat with cerebral infarction obviously, reduce the area of cerebral infarction, decrease water content in infracted brain tissue, reduce the peroxidation damage of lipoid in brain tissue and raise the acute oxygen lack tolerance of mouse and thus has excellent treat effect on cerebral infarction.

The present invention relates to a new use of 20(S)-protopanoxadiol, and in particular, to an application of 20(S)-protopanoxadiol in preparing the medicines for preventing and treating ischemic heart diseases. Pharmacodynamics studies have found that 20(S)-protopanoxadiol can reduce myocardial histological damages caused by ischemia and ischemia reperfusion, reduce enzyme indicators related to infarct size and myocardial necrosis, and reduce the drift of J-spot on an electrocardiogram.

Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and / or decreasing the incidence and / or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK) activity and / or β-ARK expression.

The present invention provides methods for treating ischemic diseases, which comprise the step of administering angiopoietin-1 (Ang1) or an Ang1-encoding vector. The present invention also provides ischemic disease treatment kits which comprise Ang1. Ang1-expressing vectors were prepared, and each was administered alone intramyocardially to rats in the acute phase of myocardial infarction to express Ang1 in the local cardiac muscle. The results indicate that marked effects have been obtained, such as decrease in post-infarction mortality rate, increase in blood vessel number in myocardium, reduction of myocardial infarct size, and improvement of cardiac function. Administration of the required VEGF was not necessary for the angiogenic activity of Ang1. Furthermore, when an Ang1viral expression vector was administered alone to an animal model of severe limb ischemia, in which ischemia had been induced by arterial ligation, a remarkable limb salvage effect was obtained. The Ang1 gene therapy is excellent as a safe and effective therapeutic method for ischemic diseases such as ischemic heart diseases and limb ischemia.

The invention belongs to the field of traditional Chinese medicine pharmacy, and relates to the application of the specific monomer leonurine in the Chinese herbal medicine motherwort in the preparation of pharmaceutical compositions, especially the application in the preparation of medicines for preventing and treating ischemic stroke. The present invention studies the middle cerebral artery occlusion experimental model through craniotomy, and the results show that the motherurine can improve the activity of glutathione peroxidase and superoxide dismutase; reduce lipid peroxidation products The level of malondialdehyde can reduce the size of cerebral infarction; increase the expression of Bcl-2 and reduce the expression of Bax protein; reduce the degree of mitochondrial swelling and increase the level of membrane potential. The result proves that said motherwortine has obvious protective effect on ischemic brain tissue, and can be used to prepare medicines for preventing and treating ischemic apoplexy.

The invention provides a traditional Chinese medicine extract for treating ischemic heart disease, and a preparation method thereof. The extract is prepared from 5-800 parts by weight of figwort root and 10-1500 parts by weight of honeysuckle as raw materials. Proven by experiments, the extract provided by the invention has obvious effects, can reduce the infarct size induced by myocardial ischemia after coronary artery ligation of rats, and can relieve arrhythmia caused by aconitine on mice, ouabin on guinea pigs and coronary artery ligation on rats. Therefore, the extract can be used for treating ischemic heart disease and arrhythmia.

The purpose of the present invention is, when treating circulatory disease such as acute myocardial infarction, to correct a reduction in myocardial contractility and thereby prevent arrhythmia and the like, as well as to reduce infarct size. Provided is a neurostimulation device having a stimulus application part configured so as to apply a stimulus to a cervical or thoracic vagus nerve portion in a human or an animal, and a stimulus regulation part configured so as to regulate the quantity of stimulus applied from the stimulus application part to the vagus nerve portion. The stimulus regulation part establishes a quantity of stimulus that is less than a value at which adverse effects would be produced, determines the heart rate and R wave interval of the human or animal, and controls the quantity of stimulus on the basis of these determinations.

The invention relates, inter alia, to methods of treating stroke, e.g., ischemic stroke, e.g., acute ischemic stroke, and methods of reducing infarct size and / or other neurological deficits associated with stroke, e.g., ischemic stroke, e.g., acute ischemic stroke, using a VLA-4 antagonist such as natalizumab. It was discovered that VLA-4 antagonists such as natalizumab can effectively reduce the infarct size and other associated neurological deficits of a stroke, e.g., an ischemic stroke; e.g., an acute ischemic stroke, e.g., when administered within a specified time period after the onset of the stroke. Also disclosed herein are articles of manufacture and kits for the treatment of stroke, e.g., ischemic stroke, e.g., acute ischemic stroke.

The invention relates to a Folium Ginkgo extract and a medical use thereof. Concrete embodiments in the invention show that compared with existing Folium Ginkgo extracts, the Folium Ginkgo extract inthe invention has an obvious treatment effect on myocardial deficiency caused by pituitrin, can effectively avoid reperfusion injury of rats and significantly reduce the infarct size, and has a bettertreatment effect on cardiovascular diseases. A preparation technology of the Folium Ginkgo extract, further provided in the invention, has the advantages of high yield and stable quality in the obtained product, simple extraction process, suitableness for industrial large-scale production, and convenience in promotion and application of the Folium Ginkgo extract.

The present invention describes a particle secreted by mesenchymal stem cells and comprising at least one biological characteristic of mesenchymal stem cells. The biological properties may comprise biological activities of mesenchymal stem cell conditioned medium (MSC-CM), such as cardioprotection or reduction in infarct size. The particles may comprise vesicles or exosomes.

The invention belongs to the field of pharmaceutical chemistry and particularly relates to application of a specific NDGA analogue to the preparation of an antioxidant drug and an anti-ischemic apoplexy treatment drug. The NDGA analogue not only can protect H2O2-induced PC12 cell injury and inhibit MDA and ROS production, but also can obviously activate a Keap1 / Nrf2 / ARE antioxidant pathway; through in-vivo experiment, the infarct size of a rat MCAO model can be obviously reduced, and nerve scores can be improved.

Methods of preventing sustained monomorphic ventricular tachycardia following myocardial ischemia, decreasing infarct size and / or decreasing the incidence and / or maximum intrinsic rate of very rapid ventricular triplets following myocardial ischemia is disclosed. The methods involve administering an effective amount of a composition that inhibits substantial loss of beta-adrenergic receptor kinase (β-ARK) activity and / or β-ARK expression.